Global Blood Therapeutics Inc buy stratec
Start price
14.12.17
/
50%
€36.49
Target price
04.11.21
€83.14
Performance (%)
-7.61%
End price
05.11.21
€33.71
Summary
This prediction ended on 05.11.21 with a price of €33.71. With a performance of -7.61%, the BUY prediction by stratec finished with a loss. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Global Blood Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | -4,93 % | -11,98 % | -3,49 % | 44,54 % |
| iShares Nasdaq 100 | -2,63 % | -2,22 % | 13,78 % | 80,99 % |
| iShares Nikkei 225® | -4,73 % | -10,90 % | 19,71 % | 45,26 % |
| iShares S&P 500 | -2,54 % | -3,54 % | 8,88 % | 61,12 % |
Comments by stratec for this prediction
In the thread Global Blood Therapeutics Inc diskutieren
stratec stimmt der Buy-Einschätzung von klostergang zu
stratec stimmt am 14.12.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 42,5$ zu.
Überschrift: Global Blood Th., mit Produktentwicklung für SCD und Hypoxämie#
14.12.2017 Global Blood Therapeutics (NASDAQ:GBT) price raised to $70 (83% upside) from $51 by Needham citing expected positive results from the Phase 3 HOPE study of voxelotor in sickle cell disease.
The FDA granted the company's lead candidate voxelotor Breakthrough Therapy for the treatment of sickle cell disease. It has a similar designation in Europe. Voxelotor is an oral once-daily therapy that works by increasing hemoglobin's affinity for oxygen.
Kursziel geändert auf 83,14
In the thread Trading Global Blood Therapeutics Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten